GlassScriptPhysician profile
Nhu T Bruce
NPI 1609922210
$10,308.55
in general payments reported to CMS, 2019-2025
61 companies · $1,969 in 2025
The $1,969 reported for 2025 was more than what 78% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $1,079 · 2021: $1,354 · 2022: $920 · 2023: $1,851 · 2024: $1,909 · 2025: $1,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,230 · Travel and Lodging: $292 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,230.18 |
| Travel and Lodging | $292.08 |
| Education | $206.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,420.60 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,038.08 | 2019-2025 | |
| Pfizer INC. | $757.44 | 2019-2025 | |
| Janssen Research & Development, LLC | $731.44 | 2023-2025 | |
| Allergan, INC. | $533.01 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $438.06 | 2020-2024 | Austedo Xr, Ajovy |
| Biogen, INC. | $431.48 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Alexion Pharmaceuticals, INC. | $342.75 | 2019-2025 | Ultomiris, Soliris |
| Astrazeneca Pharmaceuticals LP | $285.89 | 2021-2024 | Andexxa |
| Abbott Laboratories | $281.99 | 2022-2025 | Infinity, Proclaim |
| Emd Serono, INC. | $274.20 | 2023-2025 | Mavenclad |
| Grifols USA, LLC | $246.76 | 2019-2023 | Gamunex-C |
| Amgen INC. | $242.16 | 2020-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $214.86 | 2020-2025 | Rexulti |
| Tg Therapeutics, INC. | $196.20 | 2024-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhu Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.